Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Hwang, Jun Eul ^a   Yoon, Ju Young ^a   Bae, Woo Kyun ^a   Shim, Hyun Jeong ^a   Cho, Sang Hee ^a   Chung, Ik Joo ^a,b  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University Research Institute of Medical Sciences   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CEPHALOSPORIN; CREATININE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; LACTATE DEHYDROGENASE; PREDNISONE; STEM CELL FACTOR RECEPTOR; STEROID; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AGED; ANEMIA; ANOREXIA; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EOSINOPHILIA; EPIGASTRIC PAIN; EXFOLIATIVE DERMATITIS; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MACULOPAPULAR RASH; MALE; NEEDLE BIOPSY; OCULAR PRURITUS; PERIORBITAL EDEMA; PERITONEUM METASTASIS; PRURITUS; SIDE EFFECT; SKIN MANIFESTATION; UREA NITROGEN BLOOD LEVEL; VISUAL DISORDER; WEAKNESS; CHEMICALLY INDUCED DISORDER; NEUTROPENIA; PATHOLOGY; PROGNOSIS; RASH;

AGED; ANTINEOPLASTIC AGENTS; EXANTHEMA; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; NEUTROPENIA; PIPERAZINES; PROGNOSIS; PYRIMIDINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77955593646     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-438     Document Type: Article

References (19)

1. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007, 369:1731-1741. 10.1016/S0140-6736(07)60780-6, 17512858.
2. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005, 41:1751-1757. 10.1016/j.ejca.2005.04.034, 16098458.
3. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480. 10.1056/NEJMoa020461, 12181401.
4. Van Glabbeke M, Verweij J, Casali PG, Simes J, Le Cesne A, Reichardt P, Issels R, Judson IR, van Oosterom AT, Blay JY. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 2006, 42:2277-2285. 10.1016/j.ejca.2006.03.029, 16876399.
5. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 2006, 5:228-231.
6. Wolter P, Schoffski P. Targeted therapies in the treatment of GIST:Adverse events and maximising the bnefits of sunitinib through proactive therapy management. Acta Oncol 2010, 49:13-23. 10.3109/02841860903287205, 19900123.
7. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003, 21:1637-1647. 10.1200/JCO.2003.11.143, 12668652.
8. Ferraresi V, Catricala C, Ciccarese M, Ferrari A, Zeuli M, Cognetti F. Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate. Anticancer Res 2006, 26:4771-4774.
9. Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS, Wang WS, Yen CC, Chen PM. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 2002, 117:620-622. 10.1046/j.1365-2141.2002.03499.x, 12028031.
10. Scott LC, White JD, Reid R, Cowie F. Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivectrade mark) for Advanced Stage Gastrointestinal Stromal Tumours. Sarcoma 2005, 9:157-160. 10.1080/13577140500349717, 2395637, 18521425.
11. Rule SA, O'Brien SG, Crossman LC. Managing cutaneous reactions to imatinib therapy. Blood 2002, 100:3434-3435. 10.1182/blood-2002-08-2431, 12412577.
12. Milojkovic D, Short K, Salisbury JR, Creamer D, du Vivier AW, Mufti GJ. Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia. Leukemia 2003, 17:1414-1416. 10.1038/sj.leu.2402991, 12835733.
13. Park MA, Volcheck GW, Guarderas JC. Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature. Allergy Asthma Proc 2004, 25:345-347.
14. Tanvetyanon T, Nand S. Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing. Ann Pharmacother 2003, 37:1818-1820. 10.1345/aph.1D184, 14632593.
15. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, Tulliez M, Giraudier S. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003, 48:201-206. 10.1067/mjd.2003.44, 12582389.
16. Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med 2001, 345:618-619. 10.1056/NEJM200108233450814, 11529225.
17. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052-1056. 10.1056/NEJM200104053441404, 11287975.
18. Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cardo C. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 1994, 42:1417-1425.
19. Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, Joensuu H, von Mehren M. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009, 27:3141-3147. 10.1200/JCO.2008.20.4818, 19451435.